Aflibercept — Discount Pricing

Other medications in Ophthalmology

• Bevacizumab Ophthalmic
• Bimatoprost
• Brimonidine
• Brinzolamide
• Cyclopentolate
• Cyclosporine Ophthalmic
• Dorzolamide
• Faricimab

About Aflibercept

Aflibercept is a crucial medication used to treat several serious eye conditions that can lead to vision loss, such as wet macular degeneration and diabetic retinopathy. Understanding how it works and managing its often high cost is vital for patients. TheDrugClub is committed to helping members access their necessary prescriptions, including specialized treatments like aflibercept, often at significant savings.

Aflibercept is a powerful medication primarily known by its brand names, Eylea and Zaltrap, though its use cases differ. While Zaltrap is used in certain cancer treatments, Eylea is widely recognized for its role in ophthalmology, addressing conditions that threaten eyesight.

What Aflibercept

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Aflibercept is approved for (FDA label)

EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of Prematurity (ROP)

Source: Read the full FDA label on DailyMed. Label effective date: July 7, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Aflibercept (FDA label)

EYLEA is a clear, colorless to pale yellow solution available as: Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose pre-filled glass syringe Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose glass vial Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose pre-filled syringe ( 3 ) Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: f96cfd69-da34-41ee-90a9-610a4655cd1c. SPL document ID: 9e18f393-aea5-48ef-8ac9-7d523f0badc0. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Aflibercept (FDA label)

The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3) ] Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion [see Warnings and Precautions (5.1) ] Increase in intraocular pressure [see Warnings and Precautions (5.2) ] Thromboembolic events [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-855-395-3248 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: f96cfd69-da34-41ee-90a9-610a4655cd1c. SPL document ID: 9e18f393-aea5-48ef-8ac9-7d523f0badc0. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Aflibercept (FDA label)

Ocular or periocular infection ( 4.1 ) Active intraocular inflammation ( 4.2 ) Hypersensitivity ( 4.3 ) 4.1 Ocular or Periocular Infections EYLEA is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation EYLEA is contraindicated in patients with active intraocular inflammation. 4.3 Hypersensitivity EYLEA is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in EYLEA. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.

Source: FDA prescribing information (DailyMed). Set ID: f96cfd69-da34-41ee-90a9-610a4655cd1c. SPL document ID: 9e18f393-aea5-48ef-8ac9-7d523f0badc0. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Aflibercept (FDA label)

Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections.

Source: FDA prescribing information (DailyMed). Set ID: f96cfd69-da34-41ee-90a9-610a4655cd1c. SPL document ID: 9e18f393-aea5-48ef-8ac9-7d523f0badc0. Label effective date: July 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.